{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:06:48Z","timestamp":1781320008318,"version":"3.54.1"},"reference-count":41,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.25122\/jml-2025-0144","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:13:21Z","timestamp":1771251201000},"page":"1094-1099","source":"Crossref","is-referenced-by-count":1,"title":["Modulation of metabolic syndrome components by oral semaglutide in hypothyroid\u2013T2DM patients: a retrospective analysis"],"prefix":"10.25122","volume":"18","author":[{"given":"Ruxandra-Mihaela","family":"Costinescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"University Emergency Hospital of Bucharest, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana-Mihaela","family":"Tilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Doctoral School, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana-Loreta","family":"Paun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin Constantin","family":"Paun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Bucharest Emergency Clinical Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Guja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","article-title":"Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity","volume":"120","author":"Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA","year":"2009","unstructured":"1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, 2009;1201640-5","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: Definitions and controversies","volume":"9","author":"Kassi E, Pervanidou P, Kaltsas G, Chrousos G","year":"2011","unstructured":"2. Kassi E, Pervanidou P, Kaltsas G, Chrousos G, Metabolic syndrome: Definitions and controversies, BMC Med, 2011;948","journal-title":"BMC Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.diabres.2009.06.020","article-title":"Metabolic syndrome defined by IDF and AHA\/NHLBI correlates better to carotid intima-media thickness than that defined by NCEP ATP III and WHO","volume":"85","author":"Ma WY, Li HY, Hung CS, Lin MS, Chiu FC, Lin CH","year":"2009","unstructured":"3. Ma WY, Li HY, Hung CS, Lin MS, Chiu FC, Lin CH, Metabolic syndrome defined by IDF and AHA\/NHLBI correlates better to carotid intima-media thickness than that defined by NCEP ATP III and WHO, Diabetes Res Clin Pract, 2009;85335-41","journal-title":"Diabetes Res Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13098-021-00641-8","article-title":"Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Belete R, Ataro Z, Abdu A, Sheleme M","year":"2021","unstructured":"4. Belete R, Ataro Z, Abdu A, Sheleme M, Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis, Diabetol Metab Syndr, 2021;1325","journal-title":"Diabetol Metab Syndr"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"21501319241309170","DOI":"10.1177\/21501319241309168","article-title":"Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians","volume":"15","author":"Peterseim CM, Jabbour K, Kamath Mulki A","year":"2024","unstructured":"5. Peterseim CM, Jabbour K, Kamath Mulki A, Metabolic Syndrome: An Updated Review on Diagnosis and Treatment for Primary Care Clinicians, J Prim Care Community Health, 2024;1521501319241309170","journal-title":"J Prim Care Community Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.14740\/jem.v0i0.945","article-title":"Evaluation of nine forms of metabolic syndrome diagnosis as risk for cardiovascular disease: an analysis of isolated and combined metabolic factors","volume":"14","author":"Vera-Ponce J, Zuzunaga-Montoya FE, Erika L, Romero MV, Loayza-Castro JA, Manrique JO","year":"2024","unstructured":"6. Vera-Ponce J, Zuzunaga-Montoya FE, Erika L, Romero MV, Loayza-Castro JA, Manrique JO, Evaluation of nine forms of metabolic syndrome diagnosis as risk for cardiovascular disease: an analysis of isolated and combined metabolic factors, J Endocrinol Metab, 2024;14194-206","journal-title":"J Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/er.2018-00163","article-title":"Thyroid dysfunction and diabetes mellitus: two closely associated disorders","volume":"40","author":"Biondi B, Kahaly GJ, Robertson RP","year":"2019","unstructured":"7. Biondi B, Kahaly GJ, Robertson RP, Thyroid dysfunction and diabetes mellitus: two closely associated disorders, Endocr Rev, 2019;40789-824","journal-title":"Endocr Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.19191\/ep19.4.s2.p017.090","article-title":"A systematic review of case-identification algorithms based on Italian healthcare administrative databases for two relevant diseases of the endocrine system: diabetes mellitus and thyroid disorders","volume":"43","author":"Zuanna TD, Pitter G, Canova C, Simonato L, Gnavi R","year":"2019","unstructured":"8. Zuanna TD, Pitter G, Canova C, Simonato L, Gnavi R, A systematic review of case-identification algorithms based on Italian healthcare administrative databases for two relevant diseases of the endocrine system: diabetes mellitus and thyroid disorders, Epidemiol Prev, 2019;4317-36","journal-title":"Epidemiol Prev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1399236","DOI":"10.3389\/fendo.2024.1399236","article-title":"Metabolic syndrome and risk of subclinical hypothyroidism: a systematic review and meta-analysis","volume":"15","author":"Zhong L, Liu S, Yang Y, Xie T, Liu J, Zhao H","year":"2024","unstructured":"9. Zhong L, Liu S, Yang Y, Xie T, Liu J, Zhao H, Metabolic syndrome and risk of subclinical hypothyroidism: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 2024;151399236","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"661160","DOI":"10.3389\/fendo.2021.661160","article-title":"The relationship between thyroid function and metabolic syndrome and its components: a cross-sectional study in a Chinese population","volume":"12","author":"He J, Lai Y, Yang J, Yao Y, Li Y, Teng W","year":"2021","unstructured":"10. He J, Lai Y, Yang J, Yao Y, Li Y, Teng W, The relationship between thyroid function and metabolic syndrome and its components: a cross-sectional study in a Chinese population, Front Endocrinol (Lausanne), 2021;12661160","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e84475","DOI":"10.7759\/cureus.84475","article-title":"Association between metabolic syndrome and subclinical hypothyroidism: a systematic review","volume":"17","author":"Karar M, Eltayeb Eltahir SM, Mohammed Ibrahim AM, Mohammed Mahmoud FS, Mohamed Abdalla SA, Hyder Mohammed AA","year":"2025","unstructured":"11. Karar M, Eltayeb Eltahir SM, Mohammed Ibrahim AM, Mohammed Mahmoud FS, Mohamed Abdalla SA, Hyder Mohammed AA, Association between metabolic syndrome and subclinical hypothyroidism: a systematic review, Cureus, 2025;17e84475","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e0135233","DOI":"10.1371\/journal.pone.0135233","article-title":"Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis","volume":"10","author":"Han C, He X, Xia X, Li Y, Shi X, Shan Z","year":"2015","unstructured":"12. Han C, He X, Xia X, Li Y, Shi X, Shan Z, Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis, PLoS One, 2015;10e0135233","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.dsx.2019.07.020","article-title":"Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus","volume":"13","author":"Elgazar EH, Esheba NE, Shalaby SA, Mohamed WF","year":"2019","unstructured":"13. Elgazar EH, Esheba NE, Shalaby SA, Mohamed WF, Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus, Diabetes Metab Syndr, 2019;132513-7","journal-title":"Diabetes Metab Syndr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1016\/j.dsx.2016.12.041","article-title":"Association between thyroid hormone parameters and dyslipidemia among type 2 diabetes mellitus patients: comparative cross-sectional study","volume":"11","author":"Wolide AD, Zawdie B, Alemayehu T, Tadesse S","year":"2017","unstructured":"14. Wolide AD, Zawdie B, Alemayehu T, Tadesse S, Association between thyroid hormone parameters and dyslipidemia among type 2 diabetes mellitus patients: comparative cross-sectional study, Diabetes Metab Syndr, 2017;11S257-62","journal-title":"Diabetes Metab Syndr"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.dsx.2016.12.017","article-title":"Prevalence of thyroid dysfunction among type 2 diabetes mellitus patients","volume":"11","author":"Jali MV, Kambar S, Jali SM, Pawar N, Nalawade P","year":"2017","unstructured":"15. Jali MV, Kambar S, Jali SM, Pawar N, Nalawade P, Prevalence of thyroid dysfunction among type 2 diabetes mellitus patients, Diabetes Metab Syndr, 2017;11S105-8","journal-title":"Diabetes Metab Syndr"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/diabetology6050041","article-title":"The intricate relationship between thyroid disorders and type 2 diabetes\u2014a narrative review","volume":"6","author":"Tilici DM, Paun DL, Arnautu AM, Mirica A, Duta C, Costea M","year":"2025","unstructured":"16. Tilici DM, Paun DL, Arnautu AM, Mirica A, Duta C, Costea M, The intricate relationship between thyroid disorders and type 2 diabetes\u2014a narrative review, Diabetology, 2025;641","journal-title":"Diabetology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1874192401105010076","article-title":"Effects of thyroid dysfunction on lipid profile","volume":"5","author":"Rizos CV, Liberopoulos EN","year":"2011","unstructured":"17. Rizos CV, Liberopoulos EN, Effects of thyroid dysfunction on lipid profile, Curr Pharm Des, 2011;576","journal-title":"Curr Pharm Des"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e210002","DOI":"10.1530\/EC-21-0002","article-title":"Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism","volume":"11","author":"Liu H, Peng D","year":"2022","unstructured":"18. Liu H, Peng D, Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism, Endocr Connect, 2022;11e210002","journal-title":"Endocr Connect"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"12797","DOI":"10.3390\/ijms222312797","article-title":"Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD","volume":"22","author":"Mavromati M, Jornayvaz FR","year":"2021","unstructured":"19. Mavromati M, Jornayvaz FR, Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD, Int J Mol Sci, 2021;2212797","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3390\/jcm14072239","article-title":"The effect of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes: a systematic review","volume":"14","author":"Krishnanda SI, Christabelle M, Yausep OE, Sugiharto C, Vincent LD, Agarwal R","year":"2025","unstructured":"20. Krishnanda SI, Christabelle M, Yausep OE, Sugiharto C, Vincent LD, Agarwal R, The effect of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes: a systematic review, J Clin Med, 2025;142239","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12020-023-03636-9","article-title":"The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis","volume":"83","author":"Wu W, Tong HM, Li YS, Cui J","year":"2023","unstructured":"21. Wu W, Tong HM, Li YS, Cui J, The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis, Endocrine, 2023;83571-81","journal-title":"Endocrine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s13300-023-01520-3","article-title":"Glycemic control, weight management, cardiovascular safety, and cost-effectiveness of semaglutide for type 2 diabetes mellitus: a rapid review and meta-analysis of real-world studies","volume":"15","author":"Wang S, Wang S, Wang Y, Luan J","year":"2024","unstructured":"22. Wang S, Wang S, Wang Y, Luan J, Glycemic control, weight management, cardiovascular safety, and cost-effectiveness of semaglutide for type 2 diabetes mellitus: a rapid review and meta-analysis of real-world studies, Diabetes Ther, 2024;15497-514","journal-title":"Diabetes Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"110605","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li A, Su X, Hu S, Wang Y","year":"2023","unstructured":"23. Li A, Su X, Hu S, Wang Y, Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis, Diabetes Res Clin Pract, 2023;198110605","journal-title":"Diabetes Res Clin Pract"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/eurheartjsupp\/suae086","article-title":"Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with type 2 diabetes","volume":"27","author":"Temporelli PL","year":"2025","unstructured":"24. Temporelli PL, Oral semaglutide: an innovative paradigm in the management of cardiovascular risk in patients with type 2 diabetes, Eur Heart J Suppl, 2025;27i1-6","journal-title":"Eur Heart J Suppl"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Villegas ECM","year":"2019","unstructured":"25. Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Villegas ECM, PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes, Diabetes Care, 2019;421724-32","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/jdi.13764","article-title":"Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: a subgroup analysis of PIONEER 9 and PIONEER 10 trials","volume":"13","author":"Yabe D, Deenadayalan S, Horio H, Kaneto H, Jensen TB, Terauchi Y","year":"2022","unstructured":"26. Yabe D, Deenadayalan S, Horio H, Kaneto H, Jensen TB, Terauchi Y, Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: a subgroup analysis of PIONEER 9 and PIONEER 10 trials, J Diabetes Investig, 2022;13975-85","journal-title":"J Diabetes Investig"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-020-00994-9","article-title":"Oral semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER subgroup analyses","volume":"12","author":"Pratley RE, Crowley MJ, Gislum M, Hertz CL, Jensen TB, Khunti K","year":"2021","unstructured":"27. Pratley RE, Crowley MJ, Gislum M, Hertz CL, Jensen TB, Khunti K, Oral semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER subgroup analyses, Diabetes Ther, 2021;121099-116","journal-title":"Diabetes Ther"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/dom.14710","article-title":"Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme","volume":"24","author":"Aroda VR, Bauer R, Christiansen E, Haluz\u00edk M, Kallenbach K, Montanya E","year":"2022","unstructured":"28. Aroda VR, Bauer R, Christiansen E, Haluz\u00edk M, Kallenbach K, Montanya E, Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme, Diabetes Obes Metab, 2022;241338-50","journal-title":"Diabetes Obes Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen A, Knop FK, Vilsb\u00f8ll T","year":"2021","unstructured":"29. Andersen A, Knop FK, Vilsb\u00f8ll T, A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes, Drugs, 2021;811003-20","journal-title":"Drugs"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/dom.14373","article-title":"Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, B\u00e6kdal TA","year":"2021","unstructured":"30. Dahl K, Brooks A, Almazedi F, Hoff ST, Boschini C, B\u00e6kdal TA, Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes, Diabetes Obes Metab, 2021;231594-603","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/biom14060687","article-title":"Implications of GLP-1 receptor agonist on thyroid function: a literature review of its effects on thyroid volume, cancer risk, functionality, and TSH levels","volume":"14","author":"Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G","year":"2024","unstructured":"31. Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G, Implications of GLP-1 receptor agonist on thyroid function: a literature review of its effects on thyroid volume, cancer risk, functionality, and TSH levels, Biomolecules, 2024;14687","journal-title":"Biomolecules"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e20697","DOI":"10.7759\/cureus.20697","article-title":"The relationship between type 2 diabetes mellitus and related thyroid diseases","volume":"13","author":"Mohammed Hussein SM, AbdElmageed RM","year":"2021","unstructured":"32. Mohammed Hussein SM, AbdElmageed RM, The relationship between type 2 diabetes mellitus and related thyroid diseases, Cureus, 2021;13e20697","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.24018\/ejmed.2023.5.3.1743","article-title":"Semaglutide-induced subclinical hypothyroidism: a case report","volume":"5","author":"Mazokopakis EE","year":"2023","unstructured":"33. Mazokopakis EE, Semaglutide-induced subclinical hypothyroidism: a case report, Eur J Med Health Sci, 2023;58-9","journal-title":"Eur J Med Health Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3390\/biom14060687","article-title":"Implications of GLP-1 receptor agonist on thyroid function: a literature review","volume":"14","author":"Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G","year":"2024","unstructured":"34. Capuccio S, Scilletta S, La Rocca F, Miano N, Di Marco M, Bosco G, Implications of GLP-1 receptor agonist on thyroid function: a literature review, Biomolecules, 2024;14687","journal-title":"Biomolecules"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/crd.0000000000000351","article-title":"Semaglutide","volume":"40","author":"Kommu S, Whitfield P","year":"2024","unstructured":"35. Kommu S, Whitfield P, Semaglutide, Pharma-Kritik, 2024;4029-31","journal-title":"Pharma-Kritik"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/17425255.2021.1955856","article-title":"Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and on the influence of co-administered tablets: an open-label, one-sequence crossover study","volume":"17","author":"Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, B\u00e6kdal TA","year":"2021","unstructured":"36. Hauge C, Breitschaft A, Hartoft-Nielsen ML, Jensen S, B\u00e6kdal TA, Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and on the influence of co-administered tablets: an open-label, one-sequence crossover study, Expert Opin Drug Metab Toxicol, 2021;171139-48","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I","year":"2021","unstructured":"37. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, Once-weekly semaglutide in adults with overweight or obesity, N Engl J Med, 2021;384989-1002","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR","year":"2019","unstructured":"38. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med, 2019;381841-51","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1080\/14796678.2025.2511412","article-title":"Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome","volume":"21","author":"MacIsaac RJ","year":"2025","unstructured":"39. MacIsaac RJ, Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome, Future Cardiol, 2025;21663-70","journal-title":"Future Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P","year":"2020","unstructured":"40. Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity, Nat Rev Endocrinol, 2020;16177-89","journal-title":"Nat Rev Endocrinol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s13300-021-01138-3","article-title":"Comparison of body mass index and waist circumference in the prediction of diabetes: a retrospective longitudinal study","volume":"12","author":"Abe M, Fujii H, Funakoshi S, Satoh A, Kawazoe M, Maeda T","year":"2021","unstructured":"41. Abe M, Fujii H, Funakoshi S, Satoh A, Kawazoe M, Maeda T, Comparison of body mass index and waist circumference in the prediction of diabetes: a retrospective longitudinal study, Diabetes Ther, 2021;122663-74","journal-title":"Diabetes Ther"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2025\/issue-12-2025\/original-article-issue-12-2025\/modulation-of-metabolic-syndrome-components-by-oral-semaglutide-in-hypothyroid-t2dm-patients-a-retrospective-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:13:33Z","timestamp":1771251213000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2025\/issue-12-2025\/original-article-issue-12-2025\/modulation-of-metabolic-syndrome-components-by-oral-semaglutide-in-hypothyroid-t2dm-patients-a-retrospective-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["JMedLife-18-1091"],"URL":"https:\/\/doi.org\/10.25122\/jml-2025-0144","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}